383 related articles for article (PubMed ID: 15763601)
21. 5 alpha-reductase activity in cultured epithelial and stromal cells from normal and hyperplastic human prostates--effect of finasteride (Proscar), a 5 alpha-reductase inhibitor.
Boudon C; Lobaccaro JM; Lumbroso S; Lechevallier E; Mottet N; Gibelin B; Sultan C
Cell Mol Biol (Noisy-le-grand); 1995 Dec; 41(8):1007-15. PubMed ID: 8747081
[TBL] [Abstract][Full Text] [Related]
22. [Epididymis in an experimental model of DHT deficiency: immunolocalization of ERalpha and ERbeta in rat epididymal epithelial cells. In vivo and in vitro studies].
Kolasa A
Ann Acad Med Stetin; 2006; 52(2):13-21; discussion 21. PubMed ID: 17633123
[TBL] [Abstract][Full Text] [Related]
23. Development of a new gas chromatography-mass spectrometry (GC-MS) methodology for the evaluation of 5α-reductase activity.
Amaral C; Cunha SC; Fernandes JO; Tavares da Silva E; Roleira FM; Teixeira N; Correia-da-Silva G
Talanta; 2013 Mar; 107():154-61. PubMed ID: 23598206
[TBL] [Abstract][Full Text] [Related]
24. Increased androgen receptor and remodeling in the prostatic stroma after the inhibition of 5-alpha reductase and aromatase in gerbil ventral prostate.
Corradi LS; Góes RM; Vilamaior PS; Taboga SR
Microsc Res Tech; 2009 Dec; 72(12):939-50. PubMed ID: 19484778
[TBL] [Abstract][Full Text] [Related]
25. Steroid 5alpha-reductase inhibitors.
Flores E; Bratoeff E; Cabeza M; Ramirez E; Quiroz A; Heuze I
Mini Rev Med Chem; 2003 May; 3(3):225-37. PubMed ID: 12570838
[TBL] [Abstract][Full Text] [Related]
26. Evidence for the regulation of prostatic oxytocin by gonadal steroids in the rat.
Jenkin L; Nicholson HD
J Androl; 1999; 20(1):80-7. PubMed ID: 10100477
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of 5alpha-reductase blocks prostate effects of testosterone without blocking anabolic effects.
Borst SE; Lee JH; Conover CF
Am J Physiol Endocrinol Metab; 2005 Jan; 288(1):E222-7. PubMed ID: 15367394
[TBL] [Abstract][Full Text] [Related]
28. New progesterone derivatives as inhibitors of 5alpha-reductase enzyme and prostate cancer cell growth.
Cabeza M; Bratoeff E; Heuze I; Rojas A; Terán N; Ochoa M; Ramírez-Apan T; Ramírez E; Pérez V; Gracia I
J Enzyme Inhib Med Chem; 2006 Aug; 21(4):371-8. PubMed ID: 17059168
[TBL] [Abstract][Full Text] [Related]
29. CGP 53153: a new potent inhibitor of 5alpha-reductase.
Häusler A; Allegrini PR; Biollaz M; Batzl C; Scheidegger E; Bhatnagar AS
J Steroid Biochem Mol Biol; 1996 Feb; 57(3-4):187-95. PubMed ID: 8645628
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of androgen synthesis in human testicular and prostatic microsomes and in male rats by novel steroidal compounds.
Nnane IP; Kato K; Liu Y; Long BJ; Lu Q; Wang X; Ling YZ; Brodie A
Endocrinology; 1999 Jun; 140(6):2891-7. PubMed ID: 10342882
[TBL] [Abstract][Full Text] [Related]
31. Steroids with a carbamate function at C-17, a novel class of inhibitors for human and hamster steroid 5alpha-reductase.
Bratoeff E; Sainz T; Cabeza M; Heuze I; Recillas S; Pérez V; Rodríguez C; Segura T; Gonzáles J; Ramírez E
J Steroid Biochem Mol Biol; 2007 Oct; 107(1-2):48-56. PubMed ID: 17629476
[TBL] [Abstract][Full Text] [Related]
32. Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer.
Nnane IP; Kato K; Liu Y; Lu Q; Wang X; Ling YZ; Brodie A
Cancer Res; 1998 Sep; 58(17):3826-32. PubMed ID: 9731491
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological evaluation of novel unsaturated carboxysteroids as human 5α-reductase inhibitors: a legitimate approach.
Aggarwal S; Thareja S; Bhardwaj TR; Haupenthal J; Hartmann RW; Kumar M
Eur J Med Chem; 2012 Aug; 54():728-39. PubMed ID: 22776417
[TBL] [Abstract][Full Text] [Related]
34. Fungi test for evaluation of new antiandrogenic molecule.
Cabeza M; Quiroz A; Bratoeff E; Heuze I; Ramírez E; Murillo E
Proc West Pharmacol Soc; 2000; 43():29-30. PubMed ID: 11056949
[TBL] [Abstract][Full Text] [Related]
35. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
Rittmaster RS
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and pharmacological evaluation of new progesterone esters as 5alpha-reductase inhibitors.
Ramírez E; Cabeza M; Bratoeff E; Heuze I; Pérez V; Valdez D; Ochoa M; Teran N; Jimenez G; Ramírez T
Chem Pharm Bull (Tokyo); 2005 Dec; 53(12):1515-8. PubMed ID: 16327180
[TBL] [Abstract][Full Text] [Related]
37. Molecular interactions of progesterone derivatives with 5 alpha-reductase types 1 and 2 and androgen receptors.
Bratoeff E; García P; Heuze Y; Soriano J; Mejía A; Labastida AM; Valencia N; Cabeza M
Steroids; 2010 Jul; 75(7):499-505. PubMed ID: 20359488
[TBL] [Abstract][Full Text] [Related]
38. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
39. Theaflavin-3,3'-digallate and penta-O-galloyl-beta-D-glucose inhibit rat liver microsomal 5alpha-reductase activity and the expression of androgen receptor in LNCaP prostate cancer cells.
Lee HH; Ho CT; Lin JK
Carcinogenesis; 2004 Jul; 25(7):1109-18. PubMed ID: 14963012
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
Gao W; Kearbey JD; Nair VA; Chung K; Parlow AF; Miller DD; Dalton JT
Endocrinology; 2004 Dec; 145(12):5420-8. PubMed ID: 15308613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
